Liver kinase B1: a master regulator of vascular smooth muscle cell fate and vascular metabolic homeostasis?

血管平滑肌 调节器 主调节器 平衡 生物 细胞生物学 内科学 内分泌学 医学 平滑肌 转录因子 生物化学 基因
作者
Meredith Whitehead,Catherine M. Shanahan
出处
期刊:Cardiovascular Research [Oxford University Press]
卷期号:120 (14): 1654-1656
标识
DOI:10.1093/cvr/cvae197
摘要

This editorial refers to ‘Regulation of Ptbp1-controlled alternative splicing of pyruvate kinase muscle by liver kinase B1 governs vascular smooth muscle cell plasticity in vivo’, by Z. Cai et al., https://doi.org/10.1093/cvr/cvae187. Aortic aneurysm (AA) is a prevalent degenerative disease of the aorta and the 19th leading cause of death globally.1 It is usually asymptomatic until rupture when it has a mortality rate of 80%. There are currently no effective therapies other than open surgery or endovascular repair, and challenges in detection and identification of small aneurysms mean treatment cannot be targeted to lesions prior to rupture or need for surgery. It is critical therefore to understand the trajectory of AA and dissection and to identify novel diagnostic biomarkers and therapeutic targets. Vascular smooth muscle cells (VSMCs) in the medial layer of healthy blood vessels are crucial to maintaining contractility and vascular tone. Under stress or stimulation by pathological factors, VSMCs can undergo phenotypic switching, enhancing proliferation and migration capacity and differentiation into various cell types, including osteoblast-like, macrophage-like, and chondrocyte-like cells. VSMC differentiation and heterogeneity together with extracellular matrix (ECM) remodelling are key processes in the development of AA; however, current models have rarely recapitulated the earliest events and time-course of disease.2 The VSMC-specific, inducible LKB1 knock-out (KO) mouse model presented in the study by Cai et al. closely recapitulates the progression of AA.3 Integrating data from physiological measurements, single-cell analysis, imaging, and genetics, the authors identify a new aspect of this multifaceted disease and provide evidence for liver kinase B1 (LKB1) as a master regulator of VSMC fate and maintenance of vascular homeostasis. LKB1 is known to phosphorylate AMP-activated protein kinase (AMPK) and AMPK-related kinases involved in regulating cell growth, metabolism, migration, and polarity.4 Recently, the importance of LKB1 in cardiovascular disease has been established with LKB1 absence shown to cause myocardial hypertrophy, cardiac dysfunction, and atherosclerosis.5 Interestingly, LKB1 expression was decreased in human abdominal AA (AAA) samples, and this was accompanied by an increase in osteo-chondrocyte and fibroblast markers. VSMC-specific deletion of LKB1 in mice was embryonically lethal using the Tagln-Cre promoter. However, when it was deleted exclusively in VSMCs of adult mice using the tamoxifen-inducible Mhy11-Cre, it caused death within 8 months with 95% of mice spontaneously developing aortic dilation, aortic and/or arterial aneurysms, and rupture. LKB1-KO also increased vascular stiffness, highlighting the critical role of LKB1 in maintaining vascular health. Single-cell RNA sequencing 1-month post–LKB1-KO induction demonstrated a phenotypic switch of VSMCs from a contractile state to an ‘early modulated’ state, associated with loss of contractility markers and increase in inflammatory markers. At later stages, 3.5- and 4.5-month post-induction, there was differentiation into fibroblast-like and chondrocyte-like phenotypes, with significant collagen and proteoglycan deposition, ECM remodelling, and degradation of elastic fibres. At 6 months, there was expression of osteoblast marker, osteopontin, and regions of calcification were detected. The phenotypic changes were triggered by a shift in the metabolic profile towards aerobic glycolysis at the early stage, as LKB1 deficiency decreased oxygen consumption and reduced mitochondrial respiration. Pyruvate kinase M2 (PKM2) was identified as the mediator of this metabolic change. LKB1-KO upregulated polypyrimidine tract binding protein (PTBP1) expression and nuclear localization, triggering alternative splicing to produce PKM2 leading to reduced pyruvate kinase activity through formation of an inactive dimer. This finding was substantiated by treatment of the mice with a PKM2 agonist which rescued VSMC phenotype and protected against aortic dilation. However, this rescue phenotype was not studied in depth, and further analysis is required to determine the extent of rescue by targeting only the PKM2 pathway. This is crucial as PTBP1 itself has been recognized as a master regulator of VSMC alternate splicing.6,7 The authors showed increased nuclear localization of PTBP1 in the LKB1-KO mice, and it is likely that other targets of PTBP1 are also affected and this possibility needs further investigation. This study also opens up avenues for further investigation as there are questions remaining about the role of LKB1 in VSMCs. There have been several mutations identified in LKB1, causing Peutz–Jeghers syndrome and tumorigenesis, and while LBK1 is ubiquitously expressed, cells and tissues may produce different isoforms, influencing conformational state, accessibility of the nuclear localization signal and post-translational modifications which together affect enzymatic activity.8 It would be interesting to investigate the regulation of LKB1 gene expression, subcellular localization, and activity in the healthy vessel wall, as what triggers the loss of LKB1 in AA in aneurysm-prone regions remains to be elucidated. While the transformation of VSMCs was elegantly demonstrated in this study, there was no discussion of cell health or cell numbers despite AA commonly being characterized by a loss of VSMCs in the vessel wall accompanied by increased ECM deposition.2 A recent paper showed LKB1-KO mesenchymal stem cells (MSCs) exhibited marked reduction in survival compared to wild type cells,9 highlighting LKB1 as essential for cell survival under stress. The complex interplay between AA and vascular calcification was also presented. Previous clinical data have shown that the more severe the calcification, the higher the possibility of AA expansion and rupture.10 Intriguingly, in human AAA samples, there was decreased LKB1 expression which occurred concurrently with upregulation of the osteoblast marker runt-related transcription factor (RUNX2) and downregulation of the contractile marker, α-actin raising the possibility of a role of LKB1 in calcification. Indeed, calcification was also observed in LKB1-KO mice 6 months post-tamoxifen induction but not earlier, suggesting chondrocyte-like and fibroblast-like cells may eventually transform into osteoblast-like cells. However, it should be noted that in mice, chondrogenic calcification is much more prevalent than in human lesions so mechanisms may differ. Despite this caveat, a recent study showed that LKB1 expression is decreased under calcifying conditions and that LKB1 can inhibit VSMC calcification by binding mobility group box 1 (HMGB1) under normal conditions to promote its degradation thus preventing HMGB1-induced osteogenic differentiation.11 Complicating this, in MSCs the LKB1/AMPK pathway was activated in response to metformin, an antidiabetic drug, and was associated with increased RUNX2 gene and protein expression and nuclear localisation,9 highlighting the complex role of LBK1 in different cell types and tissues. In summary, this study contributes to the growing literature that implicates VSMC phenotypic plasticity and ECM remodelling in progression and exacerbation of AA (Figure 1). It not only advances understanding of AA progression but uncovers the novel LKB1–PKM2 axis as a potentially target for therapeutic intervention, and this pathway should continue to be investigated. AA progression is driven by switching of contractile VSMCs to an ‘early modulated’ phenotype and differentiation into fibroblast-like, chondrocyte-like, and eventually osteoblast-like cells. This accompanies ECM remodelling, calcification, and vascular stiffening. Changes in VSMC phenotype are regulated by a decrease in LKB1 expression, resulting in translocation of PTBP1, alternative splicing of PKM2, and its subsequent dimerization and inactivation. Cell fate switching is then triggered by a decline in mitochondrial respiration and shift towards aerobic glycolysis. The authors acknowledge the BHF Programme Grant RG/F/21/110064. Figure was made with Biorender.com.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
KGC完成签到,获得积分10
刚刚
刚刚
霁月发布了新的文献求助20
1秒前
XJH发布了新的文献求助10
2秒前
snow发布了新的文献求助10
3秒前
3秒前
等待阁完成签到 ,获得积分10
3秒前
琰sky完成签到 ,获得积分10
4秒前
4秒前
机灵夜云发布了新的文献求助10
5秒前
lawang发布了新的文献求助10
5秒前
xyx发布了新的文献求助10
6秒前
HL完成签到,获得积分10
6秒前
7秒前
mmnn完成签到 ,获得积分10
8秒前
小郭完成签到,获得积分20
8秒前
来路生云烟完成签到 ,获得积分10
8秒前
TUTU完成签到,获得积分10
8秒前
8秒前
余香的应助被科研通管家采纳,获得10
8秒前
充电宝的应助被科研通管家采纳,获得10
8秒前
慕青的应助被科研通管家采纳,获得10
8秒前
四季西瓜发布了新的文献求助10
8秒前
香蕉觅云的应助被鲤鱼鑫磊采纳,获得10
8秒前
无极微光的应助被科研通管家采纳,获得20
8秒前
所所的应助被科研通管家采纳,获得10
8秒前
余香的应助被科研通管家采纳,获得10
9秒前
smile发布了新的文献求助10
9秒前
orixero的应助被科研通管家采纳,获得10
9秒前
无极微光的应助被科研通管家采纳,获得20
9秒前
水煮电吹风的应助被KGC采纳,获得10
9秒前
充电宝的应助被科研通管家采纳,获得10
9秒前
NexusExplorer的应助被科研通管家采纳,获得10
9秒前
Owen的应助被科研通管家采纳,获得10
9秒前
传奇3的应助被科研通管家采纳,获得10
10秒前
10秒前
Jing完成签到,获得积分10
10秒前
syvshc的应助被科研通管家采纳,获得10
10秒前
领导范儿的应助被科研通管家采纳,获得10
10秒前
CipherSage的应助被科研通管家采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187412
求助须知:如何正确求助?哪些是违规求助? 9575481
关于积分的说明 21841736
捐赠科研通 7785184
什么是DOI,文献DOI怎么找? 3434949
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481846